The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and increasing demand for home healthcare solutions. Key players like Abbott and Medtronic are innovating with integrated continuous glucose monitoring systems. This expansion reflects a shift toward more accessible, cost-effective diabetes management worldwide.
Deutsche Bank upgraded Intuitive Surgical from Sell to Buy despite a 33% stock drop in 2026, citing its attractive valuation with a forward P/E ratio of 35, well below its five-year average of 54. The company maintains a strong market position with o...
Intuitive Surgical is rated a Hold with a price target of $426.65, implying a 9.17% upside. The company's growth potential lies in untapped Ambulatory Surgery Center (ASC) procedure volume and the limited threat from remanufacturing, which currently ...
Intuitive Surgical's stock has fallen over 30% this year, yet the company continues to grow its installed base of surgical robots and recurring revenue from instruments and services. The da Vinci system fleet expanded 12% in Q2 2026, with recurring r...
Intuitive Surgical's stock is down 34% year-to-date, trading at $373.71 versus an average Wall Street target of $477.25, reflecting a 28% discount. The decline followed slower-than-expected growth guidance and tariff pressures, but the company contin...
